Compare FFWM & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FFWM | MLYS |
|---|---|---|
| Founded | 1990 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 521.3M | 3.1B |
| IPO Year | 2014 | 2023 |
| Metric | FFWM | MLYS |
|---|---|---|
| Price | $6.22 | $37.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $6.17 | ★ $47.33 |
| AVG Volume (30 Days) | 642.6K | ★ 1.6M |
| Earning Date | 01-29-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $159,621,000.00 | N/A |
| Revenue This Year | $166.48 | N/A |
| Revenue Next Year | $6.86 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 47.55 | N/A |
| 52 Week Low | $4.42 | $8.24 |
| 52 Week High | $6.47 | $47.65 |
| Indicator | FFWM | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 66.10 | 44.37 |
| Support Level | $6.00 | $36.01 |
| Resistance Level | $6.41 | $38.40 |
| Average True Range (ATR) | 0.18 | 1.80 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 77.78 | 42.69 |
First Foundation Inc is a financial services company. It is engaged in providing investment management and financial planning services for high-net-worth individuals, retirement plans, charitable institutions, and private foundations. The company focuses on segments namely Banking and Wealth Management. It also offers loans to individuals and entities that own and operate multifamily residential and commercial real estate properties as well as business banking products and services to small to moderate-sized businesses, professional firms, and consumer banking products and services to individuals.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.